Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254107 | 0.85 | KDM4E (0.51) | HDAC6MEN1KMT2AHSD17B10GAA | |
| SCHEMBL12374636 | 0.82 | SMN1; SMN2 (0.57) | L3MBTL1MEN1KMT2AHSD17B10GAA | |
| SCHEMBL5320022 | 0.78 | ADORA2A (0.49) | HDAC6MEN1KMT2APOLB | |
| SCHEMBL1144927 | 0.77 | HCAR3 (0.55) | HDAC6L3MBTL1HCAR3HSD17B10HTT | |
| SCHEMBL554569 | 0.77 | HSD17B10 (0.64) | L3MBTL1HCAR3MEN1KMT2AHSD17B10 | |
| SCHEMBL14160614 | 0.77 | HSD11B1 (0.46) | MEN1KMT2AHSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL22121309 | 0.76 | HCAR3 (0.54) | HDAC6L3MBTL1HCAR3HSD17B10HTT | |
| SCHEMBL6235131 | 0.76 | ALDH1A1 (0.47) | MEN1KMT2AHSD17B10GAAHTT | |
| SCHEMBL5318291 | 0.76 | L3MBTL1 (0.54) | HDAC6L3MBTL1HCAR3HSD17B10GAA | |
| SCHEMBL5320026 | 0.75 | PTGER4 (0.47) | L3MBTL1HCAR3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007069053-A1 | BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | CORBETT JEFFREY WAYNE | 2009-10-29 | — | — | US | disclosed |
| EP-2097420-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Products Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008065508-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2007069053-A1 | BENZIMIDAZOLE ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | HDAC6 105/4885L3MBTL1 2534/4885HCAR3 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.